Industry

New and recent director nominees include industry trailblazers BJ Jones, Christine Lemke, Ken Ehlert and Chamath Palihapitiya BOSTON–(BUSINESS WIRE)–Akili Interactive (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili’s business combination with Social … [Read more…]

Further analysis of Phase III COMFORT™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla® PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that it is planning to … [Read more…]

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. “We are thrilled to welcome Dr. Ryder to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer. “He is joining us … [Read more…]

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/. This report is prepared based on the revised Corporate Governance Code as … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028” report has been added to ResearchAndMarkets.com’s offering. Orphan cancer drugs are novel pharmaceuticals that are indicated for the prevention, diagnosis, or treatment of rare cancers. These rare cancers are chronic and life-threatening which require proper long-term medications. As these diseases … [Read more…]

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report second quarter 2022 operating results after the close of the market on Thursday, August 4, 2022. Company management will host a conference call beginning at 4:30pm ET to discuss those results … [Read more…]

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss … [Read more…]

Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets UTRECHT, The Netherlands–(BUSINESS WIRE)–$BRKR #BRKR–At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Community-Acquired Bacterial Pneumonia (CABP) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, … [Read more…]

– Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mild hemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up – – New data also reinforce Hemlibra’s favorable safety profile, with no new safety signals observed – – There is limited information and treatment guidance on moderate … [Read more…]